BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30119067)

  • 1. Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Delineation of Focal Nodular Hyperplasia: Superiority of High-Flip-Angle Imaging.
    Sheng R; Palm V; Mayer P; Mokry T; Berger AK; Weiss KH; Longerich T; Kauczor HU; Weber TF
    J Comput Assist Tomogr; 2018; 42(5):667-674. PubMed ID: 30119067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
    Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
    BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
    Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
    Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis.
    Suh CH; Kim KW; Kim GY; Shin YM; Kim PN; Park SH
    Eur Radiol; 2015 Apr; 25(4):950-60. PubMed ID: 25537979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
    Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
    Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
    AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules.
    Kim JW; Lee CH; Kim SB; Park BN; Park YS; Lee J; Park CM
    J Magn Reson Imaging; 2017 Jun; 45(6):1599-1608. PubMed ID: 27726242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
    Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
    J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gd-EOB-DTPA MRI for focal nodular hyperplasia-like lesions in pediatric cancer survivors.
    Gu K; Jeon TY; Yoo SY; Kim JH
    Eur Radiol; 2021 Jan; 31(1):283-291. PubMed ID: 32797310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
    Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
    Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
    Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
    AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
    Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
    Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy comparison of multi-phase CT and hepatotropic contrast-enhanced MRI in the differential diagnosis of focal nodular hyperplasia: a prospective cohort study.
    Nowicki TK; Markiet K; Izycka-Swieszewska E; Dziadziuszko K; Studniarek M; Szurowska E
    BMC Gastroenterol; 2018 Jan; 18(1):10. PubMed ID: 29334905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
    Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC
    AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics.
    Grieser C; Steffen IG; Seehofer D; Kramme IB; Uktolseya R; Scheurig-Muenkler C; Hamm B; Denecke T
    Magn Reson Imaging; 2013 Jun; 31(5):755-60. PubMed ID: 23219272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis.
    Grazioli L; Bondioni MP; Haradome H; Motosugi U; Tinti R; Frittoli B; Gambarini S; Donato F; Colagrande S
    Radiology; 2012 Feb; 262(2):520-9. PubMed ID: 22282184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Value of Gadoxetic Acid-Enhanced MR Imaging to Distinguish HCA and Its Subtype from FNH: A Systematic Review.
    Guo Y; Li W; Cai W; Zhang Y; Fang Y; Hong G
    Int J Med Sci; 2017; 14(7):668-674. PubMed ID: 28824299
    [No Abstract]   [Full Text] [Related]  

  • 19. Value of discrepancy of the central scar-like structure between dynamic CT and gadoxetate disodium-enhanced MRI in differentiation of focal nodular hyperplasia and hepatocellular adenoma.
    Park HJ; Byun JH; Kang JH; Kang HJ; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Eur J Radiol; 2021 Jun; 139():109730. PubMed ID: 33930719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.